Resebidrag 2024 Schweiz, SWISS NORDIC BIO, 7 March
| Reference number | |
| Coordinator | NextCell Pharma AB |
| Funding from Vinnova | SEK 15 000 |
| Project duration | March 2024 - March 2024 |
| Status | Completed |
| Venture | Global cooperation 2024 |
Important results from the project
** Denna text är maskinöversatt ** Aim and objective was to present NextCell´s impressive data to a wider group of specialist investors.
Expected long term effects
** Denna text är maskinöversatt ** The outcome of completed meetings is that follow-up meetings and more detailed discussions can be initiated.
Approach and implementation
** Denna text är maskinöversatt ** The format for Swiss Nordic Bio is well-functioning and proven. Both companies and investors seem very satisfied with the arrangement.